Nanotech's rising star in drug delivery; Halozyme books beaucoup revenue;

> The executive director of the Birla Institute of Scientific Research provides a broad overview on the status and future of nanotechnology in medicine. Item

>Halozyme booked nearly $23 million in revenue for its fiscal 2011 third quarter. The company also touts a number of upcoming milestones, including the reintroduction of Hylenex recombinant for the dispersion and absorption of other injected drugs and fluids in hospital and ambulatory surgery centers. Release

>Arrowhead Research Corporation has published a white paper detailing its proprietary dynamic polyconjugate (DPC) technology to deliver siRNA. Release

>Alkermes' Vivitrol, an extended-release injectable drug to treat alcohol or drug dependence, has generated positive results in a new long-term 18-month study. Details

> DSM will supply Svelte a bioerodible drug carrier for a drug-eluting stent system. Story

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.